Buckley C D, Ferguson E D, Littler A J, Bossy D, Simmons D L
Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, GB.
Eur J Immunol. 1997 Apr;27(4):957-62. doi: 10.1002/eji.1830270423.
Lymphocyte function-associated-antigen-1 (LFA-1) is able to bind selectively to its ligands intercellular adhesion molecules 1 and 3 (ICAM-1 and ICAM-3), suggesting that LFA-1 can exist in distinct ligand-specific binding states. In the case of ICAM-1, apart from ligand itself and the recently cloned molecule cytohesin-1, the natural physiological regulators of LFA-1-mediated binding to ICAM-1 are unknown. We have investigated the role of ligands (ICAM-1 and ICAM-3) in LFA-1 activation by using ICAM-blocking monoclonal antibodies and a fixation protocol for "freezing" LFA-1 on the surface of cells after prior exposure to ICAM-1 and ICAM-3. These studies not only confirm that LFA-1 exists in distinct ICAM-specific activation states, but also demonstrate that ICAM-1 plays a role in the activation of LFA-1 binding to ICAM-3.
淋巴细胞功能相关抗原-1（LFA-1）能够选择性地与其配体细胞间黏附分子1和3（ICAM-1和ICAM-3）结合，这表明LFA-1可能以不同的配体特异性结合状态存在。就ICAM-1而言，除了配体本身和最近克隆的细胞衔接蛋白-1分子外，LFA-1介导的与ICAM-1结合的天然生理调节因子尚不清楚。我们通过使用ICAM阻断单克隆抗体以及一种固定方案来研究配体（ICAM-1和ICAM-3）在LFA-1激活中的作用，该固定方案用于在预先暴露于ICAM-1和ICAM-3后将LFA-1“固定”在细胞表面。这些研究不仅证实LFA-1以不同的ICAM特异性激活状态存在，还表明ICAM-1在LFA-1与ICAM-3结合的激活中发挥作用。
